ONWARD Medical | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Company Directory for ONWARD Medical

Team Bitscale

27 Mar 2026 — 1 min read

ONWARD Medical

Overview

ONWARD Medical N.V. is a medical technology company based in Eindhoven, Netherlands, founded in 2014 as a spin-off from EPFL. The company focuses on developing therapies aimed at restoring movement, function, and independence for individuals with spinal cord injuries (SCI). It has achieved significant milestones, including 10 FDA Breakthrough Device Designations and raising EUR 50.85 million in 2025 to support global expansion.

Its product offerings include advanced spinal cord stimulation platforms for functional recovery after SCI. The ARC-EX System is the first FDA-cleared and CE-marked non-invasive therapy that enhances hand strength and sensation in chronic cervical SCI, available in over 50 clinics across the US. The ARC-IM® System provides implantable spinal stimulation for managing blood pressure instability and other SCI-related symptoms, with a pivotal study in progress. Additionally, the ARC-BCI is an implanted brain-computer interface aimed at restoring movement through thought. The company collaborates with various research institutions and clinics, emphasizing a commitment to innovation and patient-centered care.

Basic Information

Industry	medical devices
Founded	2014
Revenue	80K
Headquarters	Parklaan, 5613 BH, Eindhoven, North Brabant, Netherlands
Parent Organization	Spin-off from EPFL

Contact Details

Website: onwd.com
LinkedIn: linkedin.com/company/onwdempowered

Key Focus Areas & Initiatives

Medical equipment manufacturing
Neurostimulation system
Neurotechnology platform
Functional rehabilitation
Movement therapy
Neurotechnology research
Neuroscience clinical trials
Paralysis treatment
Independence restoration
Clinical rehabilitation
Bioengineering solutions
Transcutaneous spinal cord stimulation
Implantable neurostimulator
Brain-computer interface
Spinal cord injury (SCI) therapy
Patient-centered therapy
Clinical evidence-based research
Innovative therapies
Personalized therapy
Regenerative medicine
Neuroengineering
Clinical trials
Mobility restoration
Quality of life improvement
Assistive technology
Therapeutic devices
Neurotechnology innovation partnerships

Technologies Used

Active Campaign
Apache
Atlassian Cloud
Exact Online
Google Analytics Ecommerce Tracking
Google Font API
Google Tag Manager
HTML Pro
Javascript
Microsoft 365
Mobile Friendly
Outlook
Pardot
Remote
SQL
Salesforce
Slack
Webflow
WordPress.org
YouTube

Clay API Limits, Authentication & Rate Limits Explained

Your enrichment workflow ran perfectly on 50 test records. Then you pointed it at 10,000 contacts and everything collapsed: 429 errors, duplicate CRM writes, and a credit balance that evaporated overnight. The Clay API usually is not the root cause. The root cause is treating authentication, rate limits, and

GTM Data Stack for US Outbound Teams

Outbound has changed. Spray-and-pray cadences that worked five years ago now burn through contact lists, damage sender reputation, and leave revenue teams short on pipeline. What separates high-performing US outbound teams in 2026 is not effort or headcount. It is the quality, governance, and architecture of the GTM Data Stack.

GTM Automation for VC/PE-backed Startups

Every board deck at a VC or PE-backed startup tells the same story: aggressive revenue targets, intense board pressure after funding, and the need to make every dollar of runway count. Headcount alone doesn't fix pipeline math, especially with lean SDR teams. GTM automation (systematically automating target account

B2B Email List Providers Playbook: Build Clean, Compliant Lists That Actually Convert

In B2B sales, your email list is either a growth engine or a money pit. An outdated, irrelevant, or non-compliant database does not just fail to convert, it harms deliverability, wastes rep time, and increases risk across your GTM motion. That is why choosing B2B Email List Providers (and setting